The LMAN2L Knockout Raji Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal cell population derived from the EBV-positive Raji B lymphocyte line, featuring targeted disruption of the LMAN2L gene. This product provides a heterozygous pool of knockout cells, avoiding clonal selection and thereby maintaining natural genetic heterogeneity while enabling bulk functional analyses. The polyclonal format is particularly advantageous for studies where population-level responses, such as global secretion profiles or surface receptor expression, are of primary interest.
The host Raji cell line is an Epstein?CBarr virus (EBV)-positive Burkitt lymphoma B lymphocyte model extensively used to investigate B-cell receptor (BCR) signaling, apoptosis, and EBV latency. Raji cells express surface immunoglobulin and retain robust downstream signaling cascades, making them a well-characterized system for studying lymphoid biology and post-translational modification pathways. Their suspension growth and well-annotated proteome facilitate biochemical and cell biological assays, including those focused on the early secretory apparatus.
LMAN2L encodes a mannose-binding lectin that functions as a cargo receptor for glycoprotein sorting into COPII vesicles at ER exit sites. It directly interacts with the COPII coat subunits SEC23 and SEC24 and cooperates with ER quality control chaperones calnexin (CANX) and calreticulin (CALR) to ensure correct folding and packaging of secretory cargo. Upstream, the transcription factors XBP1 and ATF6, both key mediators of the unfolded protein response, are putative regulators of LMAN2L expression. Within the early secretory pathway, LMAN2L acts in concert with SAR1, SEC23, SEC24, and ERGIC53, and among its downstream targets, immunoglobulin heavy chains represent a prominent glycoprotein client in B lymphocytes.
In the Raji B-cell context, LMAN2L-mediated traffic is essential for the surface expression and secretion of heavily glycosylated proteins, including components of the BCR and antibodies. Knockout of LMAN2L is predicted to disrupt glycoprotein maturation and ER quality control, potentially leading to intracellular accumulation of misfolded clients and attenuation of BCR signaling. The EBV-positive background adds a layer of complexity, as viral latency programs may interface with host secretory pathways. Consequently, this knockout model offers a means to dissect how defects in ER-to-Golgi transport influence B-cell activation, apoptosis, and lymphoma phenotypes.
Researchers can employ this polyclonal knockout population for a variety of assays, including Western blotting and RT-qPCR to confirm target disruption, immunofluorescence to visualize trafficking intermediates, and secretion ELISA quantitation of glycoprotein output. Flow cytometry enables profiling of surface glycoprotein expression, while co-immunoprecipitation and lectin blotting facilitate examination of LMAN2L interactomes and cargo glycosylation status. These cells are also suitable for screening libraries of small molecules or CRISPR modulators that restore secretory function. For further information about this product, please contact Ascent Research.
